Anti-epidemic Chinese medicines frequently circle tumor drugs and embark on the journey of clinical trials. Multi-pipeline product innovation is expected in the future.

Recently, Buchang Pharmaceutical (603858, SH) announced that Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., a holding subsidiary, received the re-registration approval notice of group A and group C meningococcal polysaccharide vaccines approved by Zhejiang Drug Administration, and the company's vaccine product layout reached a new level.

In recent years, as a well-known Chinese medicine enterprise in China, Buchang Pharmaceutical's proprietary Chinese medicines for cardiovascular and cerebrovascular diseases have continued to exert their strength, and its anti-epidemic Chinese medicine Xuanfei Baidu granules have frequently gone abroad. At the same time, the company is based on the whole industry layout of Chinese patent medicines such as chemical medicines and biological medicines. In the first half of this year, two cancer drugs of its subsidiaries embarked on the journey of clinical trials. At present, no similar target/dual target drugs have been approved for listing at home and abroad.

Zhao Chao, president of Buchang Pharmaceutical, once said that Buchang Pharmaceutical insists on being a scientific modern Chinese medicine. In recent years, the tenth five-year plan for the development of traditional Chinese medicine, the notice on some policies and measures to accelerate the development of traditional Chinese medicine and other favorable industry documents have been issued, which has made clear the importance of traditional Chinese medicine and innovation.

In the future, under the policy spring breeze, the innovative achievements of three-dimensional product layout of Buchang Pharmaceutical deserve attention.

Anti-epidemic Chinese medicines frequently appear, and the company's net profit in the first quarter increased by 5.9 1% year-on-year.

Buchang Pharmaceutical Co., Ltd., as a Chinese medicine enterprise that started with cardiovascular and cerebrovascular Chinese patent medicines, has always been the leader in the industry. As an expert in the field of cardiovascular and cerebrovascular diseases, its founder, Professor Zhao Buchang, put forward the slogan that brain and heart should be treated together, and curative effect is the last word, which has great influence in the fields of brain and heart treatment, Chinese medicine and pharmacy.

In 20021year, in China (urban public, urban community, county-level public, township health) (Chinese patent medicine) (cardiovascular and cerebrovascular diseases drugs), the company's comprehensive market share of Chinese patent medicine was among the best. In addition, the company ranked second in the list of top 100 Chinese medicine enterprises in China in 2020.

Buchang Pharmaceutical has always been rooted in Heze, Shandong Province, where it is registered, and is a local taxpayer. The tax payment from 20 18 to 2020 in Heze, Shandong Province is 3938 19200 yuan, 2 1559200 yuan and 2735 13700 yuan respectively.

At present, Buchang Pharmaceutical's products are still mainly concentrated in the field of cardiovascular and cerebrovascular drugs. In the past year, the company's five exclusive varieties, Naoxintong Capsule, Wenxin Granule, Danhong Injection, Gu Hong Injection and Compound Tripeptide Injection, made great contributions to the performance, among which the total sales revenue of four well-known exclusive varieties reached 7.397 billion yuan, accounting for 46.93% of the total revenue in 20021year.

In addition, the company's products also cover the treatment of gynecological diseases, diabetes, malignant tumors, digestive system and respiratory system.

However, during the epidemic prevention and control period, the most famous one for the company was Xuanfei Baidu Granule, which was approved urgently last year.

In June 5438+February last year, Buchang Pharmaceutical released the announcement of newly obtained invention patent certificate. The company's two patents, "A traditional Chinese medicine granule for resisting coronavirus and its preparation method and application" and "A traditional Chinese medicine composition for resisting coronavirus and its application in treating inflammation", have obtained the invention patent certificate issued by China National Intellectual Property Administration.

In the first half of this year, Xuanfei Baidu Granule was listed as a commonly recommended drug in the clinical treatment period (confirmed cases) by the novel coronavirus Diagnosis and Treatment Plan (Trial Ninth Edition).

On April 1 1, Buchang Pharmaceutical donated more than 10,000 boxes of Xuanfei Baidu granules to Shanghai Sixth People's Hospital, echoing a sentence often expressed by Zhao Tao, chairman of Buchang Pharmaceutical, that is, real entrepreneurs must have a strong sense of social responsibility. We must rush to the front line at a critical moment, assume social responsibility, and give back to the society with bit by bit actions.

And this famous anti-epidemic Chinese medicine also went abroad in the first half of the year.

According to the company's announcement in May, Buchang Pharmaceutical Xuanfei Baidu Granule received the drug registration approval issued by Uzbekistan and the Ministry of Health, and the company has the qualification to sell the product as a drug in Uzbekistan market.

Previously, Xuanfei Baidu Granule has been registered as a natural health care product in Canada and obtained the marketing license.

As of May 10, the sales revenue of Xuanfei Baidu Granules has reached 22,937,700 yuan; The first quarterly report of Buchang Pharmaceutical in 2022 showed that the company achieved a net profit of 430 million yuan from June to March, up 5.9 1% year-on-year.

Cancer drugs have embarked on the journey of clinical trials, and multi-channel product innovation is expected in the future.

During the two sessions this year, Zhao Chao, deputy to the National People's Congress and president of Buchang Pharmaceutical, said that Buchang Pharmaceutical has been committed to the modernization of traditional Chinese medicine with patented proprietary Chinese medicines as the core during its 30-year development, giving full play to the important role of traditional Chinese medicine in cardiovascular and cerebrovascular diseases, forming a three-dimensional product pattern based on the cardiovascular and cerebrovascular market, covering the traditional advantages of proprietary Chinese medicines and focusing on serious diseases.

The annual report shows that as of 20021and 65438+February, Buchang Pharmaceutical has 227 products under research, including Chinese medicine 12, chemical medicine 193, biological medicine 17 and medical devices. This year, the company's drug layout is still accelerating.

In terms of chemicals, in July, loratadine tablets, a subsidiary of Buchang Pharmaceutical, obtained a drug registration certificate, which can be used to relieve symptoms related to chronic idiopathic urticaria and allergic rhinitis.

In the seventh batch of national centralized procurement, Buchang Pharmaceutical's subsidiaries Shaanxi Buchang and Qionglai Yin Tian won the bid respectively, and the procurement cycle of related products Lactam tablets and mycophenolate mofetil capsules was three years, which laid a foundation for improving the company's market share and brand influence.

In terms of vaccines, in April this year, the tetravalent influenza virus split vaccine of Zhejiang Tianyuan, a holding subsidiary of Buchang Pharmaceutical, was approved by China for the collection of human genetic resources, and the third phase of clinical trials was officially launched, which can be used to stimulate the body to generate immunity against influenza virus and prevent influenza caused by this strain.

Regarding cancer drugs, in April and July this year, Buchang Pharmaceutical announced that the application for clinical trial of BC004 for injection of Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. (referred to as Luzhou Buchang), a holding subsidiary, was approved, and the application for clinical trial of BC008- 1A injection was accepted by the State Pharmaceutical Products Supervision and Administration.

The announcement shows that BC004 for injection is a recombinant anti-HER2/CD3 humanized bispecific antibody drug, which is mainly used to treat HER2-positive advanced solid tumors, including HER2-positive breast cancer, gastric cancer/gastroesophageal junction adenocarcinoma and so on. BC008- 1A injection is a double antibody drug specifically targeting PD- 1 and TIGIT, and its main indication is advanced solid tumor.

It is worth noting that for the above two drugs, there are no similar target/dual-target drugs approved for marketing at home and abroad.

In the future, the subsidiary will still be an important starting point for Buchang Pharmaceutical to adhere to the scientific and technological Chinese medicine, modern Chinese medicine and great health layout.

According to the 20021annual report, Buchang Pharmaceutical has invested in 6 companies, and plans to invest in 5 companies during the reporting period. In the first half of this year, Buchang Pharmaceutical successively invested and established subsidiaries such as Beijing Buchang Health Consulting Co., Ltd. and Changsha Zhongce Biotechnology Co., Ltd.

In March this year, the 14th Five-Year Plan for the Development of Chinese Medicine was issued, which put forward clear measures for the high-quality development of Chinese medicine in the new period. In the future, under the leadership of the policy spring breeze and the subsidiary R&D team, the innovation achievements of Buchang Pharmaceutical, a leading Chinese medicine enterprise, are still worthy of attention.

If you want to know more real-time financial news, please follow us.